Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
5.8.2021 16:00:00 EEST | Business Wire | Press release
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 10:00:00 EEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820387312/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 09:00:00 EEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819555366/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
Ant International’s FalconTST Model 2.0 Achieves SOTA, Elevating Predictive AI Application in Finance to New Levels20.8.2026 04:55:00 EEST | Press release
Ant International has introduced Falcon Time-Series Transformer (TST) AI Model 2.0, its most advanced TST model so far designed to deliver more accurate forecasting in real-world FX risk management of cross-border payments, with more industry applications to come, such as demand forecasting for supply chain management for e-commerce platforms, and predictive operations management for aviation industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819055561/en/ Falcon TST Time-Series Transformer Al Model 2.0 FalconTST 2.0 demonstrates State-of-the-Art (SOTA) performance on the Mean Absolute Scaled Error (MASE) metric on a top global public evaluation benchmark for time-series foundational models. MASE is among the most critical metrics used to evaluate time-series models. FalconTST 2.0 achieved a MASE score of 0.666 and places it at the top of the leaderboard, surpassing other TST foundational models from leading global
Grid Dynamics Earns MACH Alliance's 2026 Agent Ready Award for Production-Scale Agentic AI19.8.2026 23:05:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced it has earned MACH Alliance's 2026 Agent Ready Award, becoming one of 35 companies named in the program's inaugural cohort. Agent Ready is an advanced certification that builds upon MACH Certification, the MACH Alliance's baseline standard for open, composable, and connected technology. The honor recognizes certified members that have moved agentic AI from pilots and demos into production, at scale, with the guardrails enterprise deployment requires. Every award is independently reviewed by MACH Alliance, the vendor-neutral authority on scaling production-ready enterprise AI without vendor lock-in. For companies like Grid Dynamics, Agent Ready criteria evaluate organizational readiness at scale: named leadership, market presence, published thought leadership and production delivery. Grid Dynamics met that bar with agentic AI programs built and deliver
Xsolla Announces Multi-Year Strategic Partnership With the Good Game Club Podcast to Amplify Positive Stories From the Global Games Industry19.8.2026 19:10:00 EEST | Press release
Xsolla, a global video game commerce company, today announced a multi-year strategic partnership with Good Game Club, the independent, global podcast dedicated to sharing positive stories from the gaming ecosystem. The partnership builds on a broader effort to support the developers, publishers, and creators shaping the future of the games industry in a positive way by supporting good stories from the human side of video game businesses. The partnership spans the global events calendar, with joint podcast recordings planned each year at gamescom in Cologne and the Game Developers Conference (GDC) in San Francisco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819127662/en/ Graphic: Xsolla Xsolla and Good Game Club will collaborate on recurring editorial segments and deep-dive episodes exploring studios and stories from every corner of the industry, from up-and-coming teams to mid-tier and established developers. The coll
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
